Daniel Getts

Tolera Therapeutics, Inc. develops novel therapies and technologies for immune modulation. Its products include anti-aßTCR antibody an immune induction therapy in solid organ transplantation and graft versus host disease. The company was founded by Jake Orville, Maria Siemionow, James J. Herrmann and John J. Puisis in 2007 and is headquartered in Ann Arbor, MI.

TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.

Myeloid Therapeutics, Inc. operates as an immuno-oncology company that engages in the development of cell program to cure cancer. It offers ATAK platform, a cell therapy technology. The company was founded by Ronald Vale, Siddhartha Mukherjee, Daniel Getts, and Thomas Cahill in 2019 and is headquartered in Cambridge, MA.

Cour Pharmaceuticals Development Co., Inc. engages in the development of therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease. Its product pipeline include celiac disease, peanut allergy, multiple sclerosis, and neutralizing antibodies. The company was founded by John J. Puisis and Jim Herrmann and is headquartered in Chicago, IL.

Curate Biosciences engages in the development of a liquid biopsy platform for obtaining rare circulating tumor cells. It offers a desktop fluidic system for cell separation that pumps blood through a disposable microchip. The company was founded by Michael D. Grisham in 2002 and is headquartered in Richmond, VA.